Absci is a biopharmaceutical company developing antibody therapeutics using an AI-native platform that combines generative design algorithms with rapid laboratory validation to discover and optimize drug candidates. The company operates through multiple revenue streams: advancing its own pipeline of clinical-stage programs, such as an anti-prolactin receptor antibody candidate for hair loss and endometriosis; partnering with other pharmaceutical firms on drug discovery collaborations that generate upfront fees, research payments, and milestone and royalty income; and out-licensing early-stage programs for non-dilutive capital. The platform's core advantage lies in substantially compressing development timelines and reducing capital requirements compared to traditional approaches by iterating between computational design and wet-lab validation to optimize binding affinity, immunogenicity, and developability simultaneously.